Nov07Tue
ICON contributes to major European research study that aims to improve treatment for traumatic brain injury
Recommendations from the longitudinal observational research study will be presented today at the European Parliament
Dublin, Ireland, 7 November 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has contributed to a complex pan-European traumatic brain injury (TBI) research study involving over 4,500 patients in 65 sites in 20 European countries. ICON provided site management and source data verification (SDV) services to the study, which was supported by the European Union and led by Professor Andrew Maas from the University Hospital Antwerp (Belgium) and Professor David Menon from the University of Cambridge (UK). ICON’s Dr. Valérie Legrand, VP Project Management and a recognised expert in CNS, also provided clinical expertise as a member of the project’s Management Committee. The Lancet Neurology Commission on TBI is being launched at the European Parliament today and will set out clinical and research priorities and recommendations to address the varied challenges in TBI.
Congratulations to Deirdre McGlinchey, attorney at McGlinchey Stafford in New Orleans, who was appointed Honorary Consul of The Kingdom of The Netherlands.
Nov02Thu
Nov01Wed
Almac Group Announces Acquisition of BioClin Laboratories
Significant global expansion of existing analytical services
Craigavon, N.I., 01 November 2017 – Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of BioClin Laboratories, an independent and privately owned organisation based in Athlone, Ireland.
Established in 2002 and located in Garrycastle, just two hours away from Almac Group’s Headquarters in Northern Ireland, BioClin is internationally recognised for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.
Oct31Tue
Congratulations to Shaun Kelly, COO at IABCN Corporate Member company, KMPG, on being included in Irish America’s 2017 Wall Street 50.
Irish America magazine’s Annual Wall Street 50 recognizes the outstanding accomplishments and success of the best and the brightest Irish-American and Irish-born leaders of the financial industry.
